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Direct delivery of fluid to brain parenchyma is critical in both
research and clinical settings. This is usually accomplished through
acutely inserted cannulas. This technique, however, results in
backflow and significant dispersion away from the infusion site,
offering little spatial or temporal control in delivering fluid. We
present an implantable, MRI-compatible, remotely controlled drug
delivery system for minimally invasive interfacing with brain
microstructures in freely moving animals. We show that infusions
through acutely inserted needles target a region more than twofold
larger than that of identical infusions through chronically implanted
probes due to reflux and backflow. We characterize the dynamics of
in vivo infusions using positron emission tomography techniques.
Volumes as small as 167 nL of copper-64 and fludeoxyglucose
labeled agents are quantified. We further demonstrate the impor-
tance of precise drug volume dosing to neural structures to elicit be-
havioral effects reliably. Selective modulation of the substantia nigra,
a critical node in basal ganglia circuitry, via muscimol infusion induces
behavioral changes in a volume-dependent manner, even when the
total dose remains constant. Chronic device viability is confirmed up
to 1-y implantation in rats. This technology could potentially enable
precise investigation of neurological disease pathology in preclinical
models, and more efficacious treatment in human patients.
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Reliable delivery of therapeutics to specific brain structurespresents a major limitation in the treatment of neurological
and neuropsychiatric disorders. Failure of drug trials for these
disorders has been attributed to inadequate drug distribution
within brain structures (1). Drug targets implicated in such dis-
orders have been found in many regions of the central nervous
system, but in any individual case, the causative pathology may
be localized to a single region of the brain. Thus, broad drug
biodistribution can lead to significant off-target effects and po-
tential toxicity at therapeutic doses (2). Focal delivery of drug
could decrease adverse effects while improving treatment effi-
cacy. Current chronic focal delivery techniques are limited to
passive mechanisms with devices such as Omayya reservoirs and
Gliadel wafers (3). Acute delivery is achieved with intraventric-
ular infusions through acutely implanted needles (4). No actively
controlled chronic drug delivery system for the brain is currently
in clinical use. The use of optogenetics, designer receptors ex-
clusively activated by designer drugs, and other revolutionary
tools has begun to address the great heterogeneity of cells and
function in neural microstructures (∼1 mm3) (5–7). Even these
techniques, however, rely on acute needle injections into the
brain. New tools and therapies can be potentially created with
the strategy of targeting specific neural structures with fine
spatiotemporal resolution. Precise chemical dosing with micro-
invasive devices should enable such targeting of specific pop-
ulations of cells based on their anatomical location (8).
Mid- and deep-brain structures often contain millimeter-scale
regions critical for regulation of complex emotions and behaviors
(8, 9). Structures within the anterior cingulate cortex and stria-
tum, for example, can modulate motor activity and value-based
decision-making when specifically stimulated (8, 9). A variety of
chronically implanted neural probes have been developed and
reported in the literature (10–14). Few of these, however, are
capable of independently targeting deep structures. Current
probes are either too short to penetrate deep beneath the neo-
cortex or require a large guide tube to be placed for reliable
insertion beyond ∼1 cm, introducing significant trauma and ob-
viating the benefit of a micrometer-scale probe. Clinical drug
delivery in the brain has thus far been achieved mainly through
convection-enhanced delivery (CED) probes (15). CED probes,
however, are relatively large (1–2 mm-diameter) and designed to
target large volumes, not sub–cubic-millimeter regions (16).
We developed techniques for targeted dosing of brain micro-
structures with fine spatiotemporal control using custom-fabricated
microprobes and leveraging miniaturized neural drug delivery
systems (MiNDS) originally used for modulation of individual
neuronal activity in rodents and nonhuman primates (17). Key
findings in the current study include the use of MiNDS to selec-
tively dose brain microstructures and modulate behavior effects in
a volume-dependent manner. We report (i) chronic viability of
MiNDS probes up to 1-y postimplantation, resulting in minimal
gliosis and scar formation, (ii) positron emission tomography
Significance
The brain is composed of distinct microstructures. Many neu-
rologic and neuropsychiatric diseases arise from dysfunction of
circuits of neurons and glia affecting multiple brain regions.
Novel potential drug therapies are often delivered through
acutely inserted cannulas in the brain. We show that such
methods target a much larger region than focal chemical dos-
ing using a class of chronically implanted microprobes. We
develop techniques to quantify dynamics of deep-brain infu-
sions and show distinct diffusion behavior of different chem-
icals. Our microprobes can be independently inserted and
combine multiple fluidic lumens in a submillimeter footprint.
Studies using implanted drug delivery systems in rodents il-
lustrate our system’s ability to remotely control behavior and
the importance of volume in modulating brain regions.
Author contributions: K.B.R., C.D., A.M.G., R.L., and M.J.C. designed research; K.B.R., C.D.,
K.C.S., P.J., M.C., E.R., and C.N.-L. performed research; K.B.R., K.C.S., P.J., M.C., C.N.-L., and
M.J.C. analyzed data; and K.B.R., C.D., A.M.G., R.L., and M.J.C. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
Published under the PNAS license.
1To whom correspondence may be addressed. Email: rlanger@mit.edu or mjcima@mit.
edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1804372115/-/DCSupplemental.
Published online June 25, 2018.
7254–7259 | PNAS | July 10, 2018 | vol. 115 | no. 28 www.pnas.org/cgi/doi/10.1073/pnas.1804372115
(PET) techniques to quantify drug microdosing kinetics, and (iii)
volume-dependent behavioral modulation in freely behaving,
awake rats. We demonstrate that the volume of drug infusion,
rather than drug dose, leads to different pharmacodynamics with
respect to neural circuit node activity. Additional findings illus-
trate that PET resolves bolus dynamics and diffusion profiles of
various infusates in vivo with millimeter-scale resolution. We
characterize distinct infusion kinetics based on pharmacodynamics
as well as electrochemical characteristics of media infused such as
molecular charge and size.
Results and Discussion
We first determined the volume of brain targeted by acute needle
injection. Radioactive copper-64 (Cu-64) (1.67 μL) was infused
into the rat substantia nigra (SN) [anterioposterior (AP) −5.0 mm,
mediolateral: −2.2 mm, dorsoventral: −8.2 mm] using established
acute injection protocols in the literature (18). The rat was then
immediately imaged using PET (Fig. 1A). We compared the PET
findings to an identical infusion (1.67 μL; Cu-64) through a
chronically implanted probe, up to 2-mo postimplantation (Fig.
1B). Acute needle infusions targeted a brain volume over twofold
higher than that targeted using chronic probes (12.92 ± 2.148 mm3
vs. 4.497 ± 0.393 mm3) (Fig. 1C), as measured using PET. Infu-
sions through chronic probes allow for deep-brain chemical dosing
with significantly greater spatial specificity.
Our probe was manufactured by combining commercially avail-
able components on custom microfabricated poly(pyromellitic
dianhydride-co-4,40-oxydianiline) amic acid (PI) alignment tem-
plates. Templates were fabricated using soft lithography as shown in
SI Appendix, Fig. S1. Individual borosilicate fibers (inner diameter =
20 μm and outer diameter = 60 μm) served as microfluidic chan-
nels. Fibers were then placed within a polyimide outer shell to
enhance viability and stability, and cemented to an acrylonitrile
butadiene styrene hub (Fig. 1D). A custom 3D printed cap was
coimplanted to protect the protruding top of the MiNDS probe.
Modular manufacturing techniques offer versatility to inter-
change individual components without changing the overall as-
sembly process. A significant drawback of widespread metallic brain
probes is the inability to use magnetic resonance imaging (MRI)
after implantation (19). Our probe could be imaged using T2-
weighted MRI without observable tissue distortion artifacts (Fig.
1E). Varying dimensions of the outer shell allows for optimization
of cross-section and rigidity of the probe. A mechanically robust
outer shell obviates the need of an insertion shuttle and avoids
buckling during insertion. This can also be substituted for stiffer
materials such as stainless steel (Fig. 1F). Three-dimensional finite-
element analysis (FEA) mechanical simulations guided the opti-
mization of probe dimensions. MRI-compatible polyimide probes
experience critical buckling loads, Pcr, of 31.2 mN. The tunable
length allows targeting of any brain region in various small and
large animal species. We also fabricated two stainless-steel probes
with lengths of 1 cm (S-MiNDS) and 10 cm (L-MiNDS), with Pcr
equal to 1.79 and 17.8 mN, respectively (Fig. 1G). All probes were
designed to have buckling loads at least an order of magnitude
above brain penetration forces (20, 21) (Fig. 1G and SI Appendix,
Fig. S2). The number and modality of components within MiNDS
can be modified as needed. We also fabricated probes containing a
tungsten recording electrode together with two fluidic channels
(Fig. 1F and SI Appendix, Fig. S3). Components were aligned in a
borosilicate trilumen aligner using vacuum tweezers (SI Appendix,
Fig. S4). Such versatility permits for implementations of this tech-
nology in multiple contexts, including one-step optogenetics and
electrofluidic interfacing (22).
Imaging of submicroliter volume infusions into the brain has
thus far been achieved by ex vivo autoradiography or other
anatomical methods (23, 24). The inherent limitation of these
techniques is the inability to image in vivo. Here, we used PET to
image microliter-scale infusions with submillimeter spatial res-
olution in live, anesthetized animals with implanted probes (Fig.
2A). We infused 1.67 μL of (i) unbound Cu-64, (ii) PEGylated
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Fig. 1. Chronic MiNDS probes for focal deep-brain interfacing. (A) PET/computed tomography (PET/CT) scans of rat head following 2-μL acute injection of Cu-64
in vivo. (B) Illustration of implanted short, minimally invasive drug delivery system (S-MiNDS) probe in a rat. (Inset) PET images of 2-μL infusion of Cu-64 through
chronically implanted probe. (C) Size of brain region targeted using infusion through acutely inserted needle and chronic implant. (Error bars represent SD. **P <
0.005, unpaired Student’s t test.) (D) Schematic of cross-section of S-MiNDS probe showing two borosilicate fibers aligned on a polyimide (PI) template and
encapsulated by an outer shell. (E) Picture of nonmetallic (PI) S-MiNDS probe and MRI image of implanted probe with overlaid probe outline. (F) Picture of
stainless-steel (SS) S-MiNDS probe with two borosilicate fibers and tungsten electrode with Mill-Max pin connector. (G) FEA mechanical simulations examining
critical buckling loads, Pcr, for PI and SS probes of various lengths. Also shown is primary buckling mode with normalized displacement magnitude.
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Cu-64 (PEG-Cu-64), and (iii) 2-deoxy-2-(18F)fluoro-D-glucose
(FDG) over 10 min. Imaging began simultaneously with infusion,
and was conducted in 5-min intervals for 60 min. PET data were
analyzed by measuring total activity included within two 3D re-
gions of interest (ROIs). ROI 1 encompassed the region around
the infusion bolus, and ROI 2 was defined as the bolus size at the
point of infusion (Fig. 2 B and C). The two ROIs were volu-
metrically distinct and did not overlap.
Each of the three agents displayed distinct transport and dif-
fusion kinetics. Unbound Cu-64 experienced negligible diffusion
and remained localized (Fig. 2 E–H, Q, and T and SI Appendix,
Fig. S5) within a 4.36-mm3 spherical bolus. Both PEG-Cu-64 and
FDG, by contrast, diffused readily into the surrounding paren-
chyma. We modeled the decrease in activity in ROI 2 for
PEG-Cu-64 and FDG as one phase exponential decay (Fig. 2D).
PEG-Cu-64 (Fig. 2 I–L, R, and U and SI Appendix, Figs. S6 and
S7) diffused with time constant of τ = 8.513 min. FDG diffused
more rapidly away from the infusion site (τ = 6.551 min), sug-
gesting that physical diffusion is enhanced by the relatively small
size of FDG (181 Da) compared with PEG-Cu-64 (20 kDa) (Fig.
2 M–P, S, and V and SI Appendix, Fig. S8). FDG is also ma-
nipulated by glucose transporters which could enhance clearance
and transport away from the infusion site (25). PEG transport in
the brain, by contrast, is dominated by passive diffusion and is
unaffected by physiologic uptake or clearance processes (26).
The negligible diffusion of unbound Cu-64 was likely due to
intracellular influx and sequestration of copper ions by copper
transporters, Ctr1, and metallothionein (27, 28). Normal copper
ion trafficking processes are unable to act on Cu-64 bound to
large molecules such as PEG.
The high sensitivity of PET allowed us to assess the behavior
of microliter-scale infusions of different compounds in vivo. We
assessed spatial distribution of nanoliter-scale volumes by in-
fusing 167 nL of unbound Cu-64 (SI Appendix, Fig. S9). Infusions
of, respectively, 1.67 μL and 167 nL of Cu-64 spanned spherical
volumes of 4.5 mm3 and 2.35 mm3 (SI Appendix, Figs. S5 and S9).
Our studies illustrate that focal infusions through chronically
implanted probes eliminate backflow, which is a frequent issue in
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Fig. 2. PET imaging of in vivo infusions. (A) Picture of MiNDS probe and cap chronically implanted in a rat. (B and C) Representative 3D PET image obtained
after infusion (B) and 3D ROI used for analysis (C). (D) ROI 2 total intensity profiles for Cu-64, PEG-Cu-64, and FDG infusions. (E–P) PET images of infused Cu-64
(E–H), PEG-Cu-64 (I–L), and FDG (M–P) bolus at t = 0, 10, 35, and 60 min for 10-min infusion. (Q–S) Normalized intensity profile across center of bolus at t = 10,
35, and 60 min after Cu-64 (Q), PEG-Cu-64 (R), and FDG (S) infusion onset. (T–V) Normalized sum intensity in ROI 1 and ROI 2 for Cu-64 (T, n = 4), PEG-Cu-64 (U,
n = 3), and FDG (V, n = 4) infusions. All infusion volumes, 1.67 μL. ROI 2 was individually computed for each trial such that the signal at the outer edge is 10%
of the max signal at the center. Volume of ROI 1 was set to exactly 15× that of ROI 2. (Scale bars, 1 cm for B and C, 1 mm for E–P.)
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large volume infusions. This allows for increased accuracy in
targeting specific neural structures. Although MicroPET has
been employed to detect large-volume (10–20 μL) CED infu-
sions in vivo, our protocol is an instance where noninvasive
in vivo imaging has been used to characterize submicroliter in-
fusions in the brain (29, 30).
A common cause of failure of chronically implanted neural
probes is that astrocytes and microglia migrate to the site of a
foreign probe and mount an inflammatory response to form a
glial scar (31). The scar can lead to separation of the probe from
the neural tissue, disrupting function (32). In the case of deep-
brain stimulation, gliotic scarring can necessitate increased
voltage to maintain a therapeutic range. Astrocytes and micro-
glia can also migrate into probes’ microfluidic lumens and oc-
clude the fluid output. Cellular-scale electrodes (5–10 μm) are
increasingly prevalent as neuroscience tools, due to the low
resulting gliosis (33). Analogously, we hypothesized that by
minimizing the size of the MiNDS fluid outflow (20 μm), we
could prevent cellular infiltration and thus avoid occlusion. We
used PET to detect any increase in resistance to infusion due to
gliosis and found no delay in infusion after up to 2 mo of im-
plantation (SI Appendix, Fig. S10A). Impedance measurements
of coimplanted tungsten electrodes demonstrated fluctuations
impedance values (SI Appendix, Fig. S10B). Chemical micro-
fluidic interfacing is thus as resistant to variabilities due to gliosis
as electrical interfacing.
We chronically implanted MiNDS probes in rats to assess
long-term device viability. Brain histological analysis was per-
formed for 8-wk, 6-mo, and 1-y postimplantation (Fig. 3 A–E and
SI Appendix, Fig. S11). Immunohistochemical staining showed
that the glial scar formed by astrocytes (GFAP) and microglia
(Iba1) decreased with increased implantation time, down to
150 μm after 1 y postimplantation (Fig. 3 F and G). Neuronal
viability increased with implantation time, indicating that initial
insertion trauma of the device subsided with time. Neuronal
necrosis was not detected in the vicinity of the probe after 1 y of
implantation (Fig. 3H). Implant size is a primary driver of
chronic gliosis (34). Smaller probes have been reported in the
literature. However, these require the use of a large guide can-
nula for insertion, greatly increasing trauma and subsequent
gliosis, regardless of implant size. MiNDS probes are inserted
independently, allowing for long-term stability and robust via-
bility of neurons surrounding the implant.
Attenuation of local brain circuit dynamics requires precise
temporal control of on/off dosing state. MiNDS probes were
connected to iPrecio SMP-300 micropumps to achieve remotely
controlled dosing in vivo. The fluidic functionality of MiNDS was
confirmed in vitro before implantation. SMP-300 micropumps
are intended for chronic low flow-rate, low-pressure infusion.
The fluidic resistance of round capillaries was determined by
R=
8μL
πr4
.
The hydraulic resistance is 1.59 × 1014 kg/m4 s, equivalent to a
pumping pressure of 0.44 kPa at 10 μL/h for the shortest 1-cm
capillary used. The compliant tubing of the micropump balloons
during such high-pressure infusion, resulting in fluid outflow
even when the pump is turned off. For a 10-min infusion at
10 μL/h through L-MiNDS, only 5.53% of total infusion volume
was delivered by 10 min (Fig. 4A). System compliance was mini-
mized to avoid this problem and achieve the fine control required.
Compliant styrene ethylene butylene styrene (SEBS) tubing was
replaced with noncompliant flexible fluorinated ethylene propyl-
ene (FEP) tubing. An identical 10-min 10-μL/h infusion with
FEP tubing yielded 96.6% outflow of total infusion by the end
of 10 min (Fig. 4A). FEP tubing was etched to permit bonding
of medical-grade epoxy to the tubing. The connection between
tubing and micropump was made by a 2-cm stainless-steel con-
nector to reduce the effect of remaining compliant SEBS tubing
within the pump peristaltic mechanism. In vitro testing of this
setup confirmed that MiNDS infused reliably and consistently
at flow rates across multiple orders of magnitude (0.1, 1, and
10 μL/h). The system performed with less than 7.5% or 15% over-
flow after end infusion across all flow rates through S-MiNDS
and L-MiNDS, respectively. The smallest infused volume was
33 nL (SI Appendix, Fig. S12). No significant outflow was detected
when the system was off, indicating negligible leakage due to
passive diffusion.
We implanted MiNDS to characterize the effect of volume
infused on behavioral modulation in an acute, reversible hemi-
parkinsonian rat model (35). This model utilizes unilateral infusion
of muscimol, a GABA agonist, to the SN to elicit increased con-
tralateral turning. Activation of inhibitory GABA circuits leads to
an imbalance in motor drive on the two sides of the brain, pro-
ducing circling behavior. We quantified the effect of infusion vol-
ume, rather than molecular dose, on behavior. Three volumes of
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muscimol (1.67 μL, 334 nL, or 167 nL) were infused into the SN
while maintaining an identical dose (total dose = 334 ng).
Each microfluidic fiber in an MiNDS probe was connected to
a wireless micropump (iPrecio SMP-300). Rats were implanted
with MiNDS and two pumps (Fig. 4B). Each of the pumps
implanted was filled with muscimol or saline. Each trial consisted
of three epochs. (i) Rats were first placed in an imaging chamber
and imaged to record baseline behavior. (ii) Saline was then in-
fused over 10 min (1.67 μL, 334 nL, or 167 nL). (iii) Fifty minutes
later, the other pump infused an equal volume of muscimol over
10 min. The animals were imaged for 2 h after muscimol infusion
(Fig. 4C). Behavior in each epoch was analyzed using Ethovision
software (Noldus) to calculate the total distance moved as well as
clockwise and counterclockwise rotations (Fig. 4D). The 167-nL
muscimol infusion had no discernible effect on behavior (SI Ap-
pendix, Figs. S13 and S14). Rats receiving medium volume (334 nL)
muscimol infusions displayed a twofold increase in activity and
increased rotational preference to the contralateral side (SI
Appendix, Figs. S15 and S16). No significant difference in either
distance moved or cumulative rotations was found between animals
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receiving small and medium volumes. Large volume (1.67-μL)
muscimol infusions had a significant and repeatable effect on
behavior. These rats exhibited a sixfold increase in distance
traveled over 30 min and 40-fold increase in net contralateral
rotations (Fig. 4 E and F and SI Appendix, Figs. S17 and S18).
The hemiparkinsonian effect of muscimol delivered to the SN
thus is volume-dependent rather than dose-dependent. A possible
explanation for the volume dependency is that GABA receptors
across the SN must be stimulated for significant behavioral effects
to be elicited. That is, partial inhibition leads to compensatory
mechanisms by noninhibited circuitry and therefore negligible
disturbance to the motor circuit and consequent behavioral ef-
fect. A review of previous studies investigating turning behavior
induced by muscimol delivery to the SN reveals successful be-
havior modulation with volumes as small as 100 nL (SI Appendix,
Fig. S19). These studies, however, employed acute needle in-
jections, which likely lead to backflow and wider distribution of
drug upon needle retraction (Fig. 1A). This is in contrast to the
infusions through chronically implanted probes here. Cu-64 PET
data illustrate that the 1.67-μL and 167-nL infusions target spher-
ical volumes of at least 4.5 mm3 and 2.35 mm3 (SI Appendix, Figs.
S5 and S9). Based on this estimate, only the largest volume in-
fusion (1.67 μL) spans the entire 3.2-mm3 SN (36) (Fig. 4 G–I).
Our findings suggest that effective inhibition of GABA within
the SN is only achieved by infusing sufficient volume to span the
entire SN, which was realized only by large-volume (1.67 μL)
infusions. Different molecules have different diffusivities in brain
parenchyma. Our analysis of the effects of varying volumes of
muscimol indicates that a high-concentration, small-volume point
source is not as effective in inducing neuromodulatory responses
as that of a less concentrated, larger-volume infusion.
These results demonstrate the importance of chronic focal drug
administration for chemical neural interfacing. The variability in
behavioral modulation as a result of volume highlights the im-
portance of fine-tuned local delivery to specific brain structures.
Successful modulation of the nigral function only occurred with
extensive, but still focal, coverage of the SN. The highly sensitive
PET in vivo imaging techniques developed here are essential tools
to characterize the dynamics of drug actions and microdosing in
the brain. These insights are vital when conducting optogenetic
and chemogenetic studies relying on discrete volume infusions of
virus for transfection. Neurologic disease often arises due to a loss
of normal dynamics in neural circuitry as a result of a malfunc-
tioning node (37). Modulating the pathologic node directly allows
restoration of the dynamics of the circuit (38). These collective
results are important steps toward the translation of localized
brain drug therapy to the clinic.
Materials and Methods
All animal studies were approved by the Committee on Animal Care, Mas-
sachusetts Institute of Technology. Materials and procedures for device
fabrication and characterization can be found in SI Appendix, SI Materials
and Methods. All in vivo studies and subsequent data analysis protocols are
described in SI Appendix, SI Materials and Methods.
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